The future of the Texas Compassionate Use Program, which will allow some physicians to treat epilepsy with cannabinoid-based drugs, is right here at the Texas Medical Center.
At a meeting in early January, Vyripharm Biopharmaceuticals explained to a group of politicians, decision makers and medical cannabinoid advocates how the company is educating the state legislature on the best way to implement the program.
The Texas Compassionate Use Act, signed into law on June 1, 2015, created a state licensing program for “dispensing organizations” to provide cannabis-based drugs and for doctors prescribing the drugs to join a physician registry and share information about dosages and administration.
As of December 2017, three dispensing organizations were chosen, and the companies are expected to begin dispensing in early 2018, according to media reports. Vyripharm, located in the TMC Innovation Institute’s TMCx+ incubator space, is assisting with setting the standards and guidelines for the companies as the Compassionate Use Program gets underway.
As part of the meeting, guests toured the company’s research laboratories at The University of Texas MD Anderson Cancer Center and the Medical Botanical Center of Excellence at the University of Houston’s Innovation Center in partnership with Shimadzu, a scientific instruments company.
“The Medical Botanical Center of Excellence is the first fully-comprehensive pharmaceutical and medical botanical testing blockchain platform in Texas,” Elias Jackson, Ph.D., director of scientific public relations at Vyripharm, said. “This has been four years in the making and will allow patients to have pharmaceutical grade cannabinoid products across the board.”
Vyripharm aims to set the standard in the implementation of Compassionate Use programs across the country. The center’s facility follows the same U.S. Drug Enforcement Administration and U.S. Food and Drug Administration standards set for the pharmaceutical industry, he said.
By following the product from seed to patient, Vyripharm aims to meet the needs of Texas’s program by creating guidelines that will ensure the products are safe and consistent.
“If you go to the drugstore to get Tylenol for your fever, you know you are getting the same level of acetaminophen wherever you go,” said Tori Strong, Ph.D., Vyripharm’s director of intellectual property and technology. “This is the same thing we want to do with cannabinoids.”
In addition, the company wants to research the specific effects of cannabinoids in individual patients.
“Soon, we will be able to find out how an initial dose of cannabinoids is being used by the body in a particular person, know exactly what works for them and be able to dose according to their characteristics,” Jackson said.
Baylor College of Medicine will be closed Monday, May 28 in observance of Memorial Day. https://t.co/6CNQMhyJ92
Baylor College of MedicineBaylorCollegeOfMedicine
Baylor College of Medicine will be closed Monday, May 28 in observance of Memorial Day.
TAMU Health Sciences@TAMHSC
#TAMHSC researchers are working to solve #diabetes-related blindness: https://t.co/D1Pi8CaD0H #Health
#Melanoma survivor explains how #immunotherapy #clinicaltrial and @DrSapnaPatel gave her hope. #CancerMoonShot #endcancer https://t.co/gxr9MaYsHi
MD Anderson Cancer CenterMDAnderson
Leticia Rousseve found comfort whenever she verbalized her frustrations and feelings to others who understood what she was going through as a caregiver for her husband, James, during his soft tissue sarcoma treatment. “This taught me an important lesson that I now share with others going through cancer: you are not alone.” Now, she pays it forward by volunteering with myCancerConnection, MD Anderson’s one-on-one cancer support community of patients, survivors and caregivers who have been there. #endcancer
At sprawling VA hospital in southern Dallas, a righteous battle to keep the promise to care for America's Veterans https://t.co/yBX7Jqyn6X via @dallasnews
6.1, 11:30 a.m.-1 p.m.: Join @MethodistHosp Cancer Center at St. John for a celebration and luncheon as we honor those living with a history of cancer. Register today: https://t.co/epZbgu9fA0 https://t.co/FLv19JSQs0
Today’s #VeteranOfTheDay is @USArmy Veteran M. Ross Kirk. https://t.co/Z1oqPWmWig
U.S. Department of Veterans AffairsVeteransAffairs
Today’s #VeteranOfTheDay is Army Veteran M. Ross Kirk. Ross served for 28 years and retired in 1988. He attained the rank of lieutenant colonel. Ross served two tours in Vietnam with the 4/39th Infantry Battalion, the 9th Infantry Division and the 5th Special Forces Group with the Chaplain Corps. He was also a member of the 101st Airborne Division, the 18th Airborne Corps 1st Division, and the Green Beret Parachute Demonstration Team. He wore the Green Beret on active duty for nine years and is nicknamed the “Leapin’ Deacon” due to his 225 military jumps, including 50 HALO (high altitude, low opening) jumps and 450 sport parachute jumps. Ross’ positions in the Army included Command Chaplain for the Special Operations Command (Airborne) and Senior Chaplain of the Combined Peacekeeping Forces in the liberation of Grenada. He retired at Fort Riley, Kansas in 1988 and has lived with his wife Judy in Wakefield, Kansas for 27 years. They have four children, eight grandchildren and one great-grandchild. Ross was awarded four Bronze Stars, five Air Medals, the Meritorious Service Medal with three Oak Leaf Clusters, the Joint Service Commendation Medal, the Army Commendation Medal with two Oak Leaf Clusters, the Army Achievement Medal and the Good Conduct Medal. He also earned the Ranger Tab, the Special Forces Tab and Master Parachutist and Air Assault Badges. Thank you for your service, Ross!
New @USDOT program provides free pilot training for Veterans https://t.co/z6mIJVPMlU via @Militarydotcom
New research funded by Department of Defense grants will look into why some women with estrogen receptor-positive breast cancer develop resistance to endocrine therapies. https://t.co/TMhNyXWZ8Y
Baylor College of MedicineBaylorCollegeOfMedicine
Congratulations to M.D/Ph.D. student Muhammad Saad Shamim on becoming a 2018 fellow of the Paul & Daisy Soros Fellowships for New Americans program.
#Chemobrain is real. Learn more about this common #cancer treatment side effect: https://t.co/86Kcj2AzFy #endcancer https://t.co/iH7IP2dIUv
What you need to know about #prostatecancer screening: https://t.co/Sbt5pA5B0J @oncolognews #endcancer
Dr. Elizabeth McIngvale talks about her journey with obsessive compulsive disorder. https://t.co/SxpIBc1gyA #MentalHealthAwarenessMonth